Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2013 2
2015 3
2016 5
2017 3
2019 1
2020 2
2021 2
2022 4
2023 12
2024 13
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
Emerging Targeted Therapies for HER2-Positive Breast Cancer.
Mercogliano MF, Bruni S, Mauro FL, Schillaci R. Mercogliano MF, et al. Cancers (Basel). 2023 Mar 26;15(7):1987. doi: 10.3390/cancers15071987. Cancers (Basel). 2023. PMID: 37046648 Free PMC article. Review.
Blocking soluble TNFα sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression.
Bruni S, Mauro FL, Proietti CJ, Cordo-Russo RI, Rivas MA, Inurrigarro G, Dupont A, Rocha D, Fernández EA, Deza EG, Lopez Della Vecchia D, Barchuk S, Figurelli S, Lasso D, Friedrich AD, Santilli MC, Regge MV, Lebersztein G, Levit C, Anfuso F, Castiglione T, Elizalde PV, Mercogliano MF, Schillaci R. Bruni S, et al. Among authors: mercogliano mf. J Immunother Cancer. 2023 Mar;11(3):e005325. doi: 10.1136/jitc-2022-005325. J Immunother Cancer. 2023. PMID: 36889811 Free PMC article.
BODIPY-Based Analogue of the TREM2-Binding Molecular Adjuvant Sulfavant A, a Chemical Tool for Imaging and Tracking Biological Systems.
Fioretto L, Gallo C, Mercogliano M, Ziaco M, Nuzzo G, d'Ippolito G, Follero O, DellaGreca M, Giaccio P, Nittoli V, Ambrosino C, Sordino P, Soluri A, Soluri A, Massari R, D'Amelio M, De Palma R, Fontana A, Manzo E. Fioretto L, et al. Among authors: mercogliano m. Anal Chem. 2024 Feb 27;96(8):3362-3372. doi: 10.1021/acs.analchem.3c04322. Epub 2024 Feb 13. Anal Chem. 2024. PMID: 38348659
Retraction Note: Progesterone receptor assembly of a transcriptional complex along with activator protein 1, signal transducer and activator of transcription 3 and ErbB-2 governs breast cancer growth and predicts response to endocrine therapy.
Flaqué MCD, Galigniana NM, Béguelin W, Vicario R, Proietti CJ, Russo RC, Rivas MA, Tkach M, Guzmán P, Roa JC, Maronna E, Pineda V, Muñoz S, Mercogliano MF, Charreau EH, Yankilevich P, Schillaci R, Elizalde PV. Flaqué MCD, et al. Among authors: mercogliano mf. Breast Cancer Res. 2023 Nov 2;25(1):133. doi: 10.1186/s13058-023-01735-z. Breast Cancer Res. 2023. PMID: 37919764 Free PMC article. No abstract available.
Correction: Halting ErbB-2 isoforms retrograde transport to the nucleus as a new theragnostic approach for triple-negative breast cancer.
Madera S, Izzo F, Chervo MF, Dupont A, Chiauzzi VA, Bruni S, Petrillo E, Merin SS, De Martino M, Montero D, Levit C, Lebersztein G, Anfuso F, Roldán Deamicis A, Mercogliano MF, Proietti CJ, Schillaci R, Elizalde PV, Cordo Russo RI. Madera S, et al. Among authors: mercogliano mf. Cell Death Dis. 2023 Dec 15;14(12):833. doi: 10.1038/s41419-023-06339-1. Cell Death Dis. 2023. PMID: 38102106 Free PMC article. No abstract available.
44 results